埃克替尼片联合SBRT治疗对NSCLC血清肿瘤标志物的影响

doi:10.3969/j.issn.1006-6233.2021.04.036

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1207 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the effect of Icotinib tablets combined with stereotactic body radiotherapy (SBRT) on patients with non-small cell lung cancer (NSCLC) serum tumor markers, and to provide a reference for better treatment of the disease. Method: A total of 65 NSCLC patients diagnosed and treated in our hospital from August 2017 to April 2020 were prospectively studied. They were randomly divided into a control group of 33 cases with SBRT as treatment, and an observation group of 32 cases with Icotinib tablets for combination therapy on the basis of SBRT treatment. Both groups were treated for one month. The serum tumor marker levels of patients were compared before treatment and within 4 to 12 hours after treatment. Results: After treatment, the levels of serum tumor markers CEA, CA125, CYFRA21-1 [(3.12 ± 1.45), (30.12 ± 3.25), (5.27 ± 1.89), μg / L] were significantly lower than the control group [(5.34 ± 1.83 ), (45.34 ± 4.87), (8.74 ± 2.15), μg / L]; the difference is statistically significant (P<0.05). Conclusion: The combination of Icotinib and SBRT can reduce the level of serum tumor markers to a greater extent and has a better effect.

Key words： Non-small cell lung cancer Icotinib tablets Stereotactic body radiotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Jie
	NING Peng
	LIU Haiming

Cite this article:

ZHAO Jie,NING Peng,LIU Haiming. Effect of Icotinib Combined with SBRT on Serum Tumor Markers in Patients with NSCLC[J]. HeBei Med, 2021, 27(4): 697-700.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.04.036 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I4/697

[1] Tazdait M,Mezquita L,Lahmar J,et al.Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1,IRRECIST and IRECIST criteria[J].European Journal of Cancer,2018,88(1):38~47.
[2] 杨旸,王一喆,郑春雷,等.胞外信号调节激酶通路活化促进埃克替尼耐药的非小细胞肺癌侵袭和转移[J].中国医科大学学报,2020,49(4):301~305
[3] Yang J,Yang J,Ban S,et al.Successful treatment of a miliary metastatic NSCLC patient with activating EGFR exon 20 insertion mutation with response to poziotinib[J].Journal of Thoracic Oncology,2019,14(9):e198~e200.
[4] 纪春东,于秀芹,赖永新.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察[J].河北医学,2017,23(1):100~102.
[5] Mhanna L,Milia J,Lusque A,et al.Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations[J].Journal of Clinical Oncology,2018,36(5):172~172.
[6] Remon J,N.Vilarino,Reguart N.Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions[J].Cancer Treatment Reviews,2018,64(3):21~29.
[7] Planchard D,Boyer M,Lee J S,et al.128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes[J].Journal of Thoracic Oncology,2018,13(4):S72~S73.
[8] Pranshu,Mohindra,Amit,et al.Three discipline collaborative radiation therapy (3DCRT) special debate: i would treat all early-stage NSCLC patients with SBRT.[J].Journal of applied clinical medical physics,2019,20(3):7~13.
[9] Baine MJ,Verma V,Schonewolf CA,et al.Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer[J].Lung Cancer,2018,118(4):20~26.
[10] 周磊,邵燕儿,朱泽浩,等.华蟾素胶囊联合盐酸埃克替尼片治疗晚期非小细胞肺癌临床效果研究[J].中国全科医学,2018,21(9):1047~1052.
[11] 丛日楠,谷芳,王冰.吉非替尼、厄洛替尼与埃克替尼治疗EGFR基因敏感突变晚期NSCLC患者的疗效观察[J].现代肿瘤医学,2018,26(2):216~221.